Atropine's Clinical Applications and Precautions

Clinical Applications

The American College of Cardiology recommends atropine as the first-line drug for acute symptomatic bradycardia, particularly in sinus bradycardia with associated reduced cardiac output and signs of peripheral hypoperfusion 1, 2
Atropine is particularly useful for treating symptomatic sinus bradycardia within 6 hours of onset of acute myocardial infarction symptoms, with a recommended dosage of 0.5 mg intravenously, repeated if needed every 5 minutes to a total dose of no more than 2 mg 1, 3
For ventricular asystole, the recommended dose is 1 mg intravenously, repeated in 5 minutes if asystole persists 1

The American College of Cardiology advises that doses less than 0.5 mg may paradoxically result in further slowing of the heart rate due to parasympathomimetic response 3
Atropine should be used with caution in acute myocardial infarction because parasympathetic tone has a protective effect against ventricular fibrillation and myocardial infarct extension 3
The American Heart Association notes that atropine is ineffective in patients who have undergone cardiac transplantation without evidence of autonomic reinnervation 2
The American Heart Association recommends avoiding reliance on atropine in type II second-degree or third-degree AV block with a new wide-QRS complex where the block is likely in non-nodal tissue 2

The European Respiratory Society states that anticholinergic agents like ipratropium and oxitropium have a slower onset of action (30-90 minutes) compared to β2-agonists (minutes) 5, 6
Anticholinergic agents are more effective in COPD than in asthma, according to the European Respiratory Society 5, 6
The European Respiratory Society found no evidence of tolerance to anticholinergic drugs during chronic therapy, unlike with β2-agonists 5, 6
Anticholinergic agents have fewer adverse effects compared to β2-agonists, which may cause a fall in PaO2 due to pulmonary vascular effects, as noted by the European Respiratory Society 5, 6